NCIt related terms : Monoclonal antibodies against SARS-CoV-2: tixagevimab/cilgavimab;
NCIt definition : A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab,
that are isolated from convalescent patients with severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein,
that can potentially be used for passive immunization against Coronavirus disease
2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically
target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and
entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression
of the disease and accelerate recovery, and may potentially provide temporary protection
against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2,
plays an essential role in the infection pathway of the SARS-CoV-2 virus.;
https://presse.inserm.fr/linserm-et-astrazeneca-sassocient-pour-tester-lefficacite-de-la-combinaison-danticorps-monoclonaux-azd7442-contre-la-covid-19-dans-le-cadre-de-lessai-europ/42799 2021 false false false France French scientific and technical information Cilgavimab/Tixagevimab pneumonia, viral coronavirus infections pandemics coronavirus infections COVID-19